Novartis, Pfizer, and Eli Lilly enter the market in high profile to see how pharmaceutical companies play "Internet +"

Drug collection "Buddhist" multinational pharmaceutical enterprises, the third into the Expo have joined hands with the domestic Internet pharmaceutical platform! JD.com Health, through the Hong Kong Stock Exchange listing hearing, will become the third listed Internet health care platform after Ping An Good Doctor and Ali Health! The high-gloss moment of China's Internet and medicine is coming.
between 2015 and 2019, the out-of-hospital pharmaceutical market is expanding at a 10.8 percent compound annual rate, while online sales are growing at a compound annual rate of 30.4 percent, according to the Frost Sullivan report.
25.8% of China's total retail sales of consumer goods in 2019 have been distributed online, while only 7.6% of out-of-hospital drug sales will be distributed online, and Frost Sullivan predicts that by 2030, 27.5% of medicines will be distributed online through off-the-cul-de-sham sales channels.
01 Gifeitini on-line JD.com Pharmacy Multinational pharmaceutical companies and domestic Internet giants to cooperate is not new.
its cooperation aims to focus more on patient education, slow disease management, but with the implementation of the collection, multinational pharmaceutical companies will be more pragmatic demand for Internet platforms - direct online e-commerce platform sales.
For example, in May this year, Lilly Pharmaceuticals announced the entry of 1 drug network online diabetes management platform, in addition to diabetes management and online disease education, but also clearly proposed that Lilly China's multi-diabetes drug portfolio will be provided to 1 drug network supply channels to further enhance patient access to drugs.
, multinational pharmaceutical companies have also opened up the popularization of the original research channels.
Most typically, on September 19th this year, AstraZeneta's lung cancer drugs Gifeitini (Iresha) and Oghitini (Terisha) went online in a "self-employed mode" at JD.com Pharmacy, allowing cancer patients to buy the drug at home.
the 2018 "4 plus 7" pilot city volume procurement, Gifeitini at 54.7 yuan / piece price; AstraZeneone also won the bid at 54.7 yuan/piece, while Zhengda Tianqing and Qilu Pharmaceuticals' Giffeitini tablets won the bid at 45 yuan/piece and 25.7 yuan/piece, respectively.
in the "4 plus 7" renewal work, ZhengDaTianQing and Qilu Pharmaceuticals in Chengdu and Fujian two regions to replace AstraZeneta won the Jifeitini film selection.
has been affected by the market, and AstraZeneta's Gifeitini has been seeing a decline in sales since Q2 began in 2019.
2020Q2 results from AstraZeneta, Gini's second-quarter sales were $70m, down 41 per cent year-on-year.
It is understood that there are currently Qilu Pharmaceuticals, Hengrui Pharmaceuticals, Zhengda Tianqing, Colum Pharmaceuticals, Yangzijiang and Tranno Pharmaceuticals and other enterprises of Giffeitini approved for listing, and as as a result of consistent evaluation, AstraZeneta's original research products market is bound to suffer further shocks.
online market is becoming an important marketing channel that multinational pharmaceutical companies have to consider.
02 The highly-expected new option At this year's Expo, Novarma Cancer, Pfizer China, Sveya China and other multi-national pharmaceutical companies signed a strategic cooperation agreement with Ali Health, in the field of cooperation clearly put forward the words "Internet plus medicine" services and prescription drug cooperation;
With the "Internet plus" health care payments actively promoted, "Internet plus medical" ecology is expected to be closed, Everbright Securities believes that in the context of policy promotion and increased demand, the Internet medical industry is expected to usher in multiple catalysis in 2020, the industry accelerated development of the inflection point is coming.
international pharmaceutical companies began to increase their focus on Internet innovation platforms.
the most outstanding performance is undoubtedly Pfizer strong.
, Pfizer's newly established business unit in 2019, is responsible for many of Pfizer's original heavy-duty bomb drugs that have exceeded the patent protection period, such as Lipto, Live Hi, Wan Aico and many other well-known products.
But Pfizer has embarked on a radical internal overhaul this year against a backdrop of performance pressure, as both Liputo and Live Magpie failed to make the cut in the 4-plus-7 series.
June, Pfizer announced a restructuring of its Greater China organizational structure, splitting its China business team into three divisions: hospital sales, retail, and innovative Internet medical services.
This is the first time that Pfizer, the "cosmic pharmaceutical company", has been singled out as a single division, becoming the second multinational pharmaceutical company to directly promote Internet healthcare projects, following AstraZenecon's Internet healthcare strategy program.
this time, Pfizer will improve its innovative Internet service business to the hospital group, retail group equivalent of the department, report directly to the president, enough to show that Pfizer's emphasis on Internet channels.
addition, multinational pharmaceutical executives are beginning to move to the Internet and healthcare platforms.
the usual place for multinational pharmaceutical executives to leave is to innovate or start a business in China.
but this year, the Internet pharmaceutical platform has become a new choice for multinational pharmaceutical executives, driven by the introduction of 4-plus-seven-band procurement, the emergence of innovative drugs, and the outbreak.
May 6th, Guo Anfeng, former vice president of the oncology division of Shishi Shiguibao, took up the post of Chief Innovation Officer of 1 Pharmaceutical Network, fully responsible for the operation and innovation of the company's Internet medical platform.
has worked for a number of multinational pharmaceutical companies including Pfizer, Bayer, AstraZeneta and BMS.